Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | FABP7 | O15540 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10137468 | 0.87 | KMT2A (0.54) | KMT2AEPHX2 | |
| SCHEMBL24520149 | 0.87 | KMT2A (0.54) | KMT2AEPHX2 | |
| SCHEMBL10137494 | 0.86 | KMT2A (0.55) | KMT2AEPHX2 | |
| SCHEMBL30759497 | 0.83 | KMT2A (0.55) | KMT2AEPHX2FABP7FABP5 | |
| SCHEMBL13020981 | 0.80 | KMT2A (0.57) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL21578387 | 0.80 | KMT2A (0.55) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL21578301 | 0.80 | KMT2A (0.55) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL23843568 | 0.80 | KMT2A (0.55) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL12598575 | 0.79 | KMT2A (0.54) | KMT2AEPHX2 | |
| SCHEMBL13555711 | 0.79 | KMT2A (0.54) | KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708370-B2 | Azapeptides as CD36 binding compounds | VALORISATION-RECHERCHE, LIMITED PARTNERSHIP (CA) | 2017-07-18 | — | — | US | disclosed |
| EP-2160404-B1 | AZAPEPTIDES AS CD36 BINDING COMPOUNDS | VALORISATION RECHERCHE LTD PARTNERSHIP (CA) | 2016-08-24 | — | — | EP | disclosed |
| US-20150329591-A1 | AZAPEPTIDES AS CD36 BINDING COMPOUNDS | CENTRE HOSPITALIER UNIVERSITAIRE SAINTE-JUSTINE (CA) | 2015-11-19 | — | — | US | disclosed |
| US-9115171-B2 | Azapeptides as CD36 binding compounds | VALORISATION-RECHERCHE, LIMITED PARTNERSHIP (CA) | 2015-08-25 | — | — | US | disclosed |
| US-20130203686-A1 | AZAPEPTIDES AS CD36 BINDING COMPOUNDS | INSERM (FR) | 2013-08-08 | — | — | US | disclosed |
| US-8435954-B2 | Azapeptides as CD36 binding compounds | VALORISATION-RECHERCHE, LIMITED PARTNERSHIP (CA) | 2013-05-07 | — | — | US | disclosed |
| US-20100210566-A1 | AZAPEPTIDES AS CD36 BINDING COMPOUNDS | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2010-08-19 | — | — | US | disclosed |
| EP-2160404-A1 | AZAPEPTIDES AS CD36 BINDING COMPOUNDS | UNIVERSITE DE MONTREAL (CA) | 2010-03-10 | — | — | EP | disclosed |
| WO-2008154738-A1 | AZAPEPTIDES AS CD36 BINDING COMPOUNDS | UNIVERSITE DE MONTREAL (CA) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329591-A1 | AZAPEPTIDES AS CD36 BINDING COMPOUNDS | MSR1, ASGR1, LDLR | KMT2A 2238/4885EPHX2 2196/4885HDAC3 814/4885 |
| US-20130203686-A1 | AZAPEPTIDES AS CD36 BINDING COMPOUNDS | MSR1, ASGR1, SCARB1 | KMT2A 1958/4885EPHX2 2387/4885HDAC3 936/4885 |
| US-20100210566-A1 | AZAPEPTIDES AS CD36 BINDING COMPOUNDS | GHRHR, GHSR, GNRHR | KMT2A 2301/4885EPHX2 3705/4885HDAC3 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.